<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>104(5)</volume><submitter>Al-Sawaf O</submitter><journal>Haematologica</journal><pagination>e224-e226</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6518913</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia.</pubmed_title><pmcid>PMC6518913</pmcid><pubmed_authors>Hallek M</pubmed_authors><pubmed_authors>Cramer P</pubmed_authors><pubmed_authors>Tuchscherer A</pubmed_authors><pubmed_authors>Al-Sawaf O</pubmed_authors><pubmed_authors>Eichhorst B</pubmed_authors><pubmed_authors>Scheid C</pubmed_authors><pubmed_authors>von Tresckow B</pubmed_authors><pubmed_authors>Fischer K</pubmed_authors><pubmed_authors>Frenzel LP</pubmed_authors><pubmed_authors>Holtick U</pubmed_authors><pubmed_authors>Herling CD</pubmed_authors><pubmed_authors>Sasse S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia.</name><description/><dates><release>2019-01-01T00:00:00Z</release><publication>2019 May</publication><modification>2024-11-12T05:14:10.58Z</modification><creation>2024-11-12T05:14:10.58Z</creation></dates><accession>S-EPMC6518913</accession><cross_references><pubmed>30792201</pubmed><doi>10.3324/haematol.2018.212837</doi></cross_references></HashMap>